Literature DB >> 23680872

Modifying mesoporous silica nanoparticles to avoid the metabolic deactivation of 6-mercaptopurine and methotrexate in combinatorial chemotherapy.

Wenjing Wang1, Chenjie Fang, Xiaozhu Wang, Yuxi Chen, Yaonan Wang, Wei Feng, Chunhua Yan, Ming Zhao, Shiqi Peng.   

Abstract

Mesoporous silica nanoparticles with amino and thiol groups (MSNSN) were prepared and covalently modified with methotrexate and 6-mercaptopurine to form 6-MP-MSNSN-MTX. In the presence of DTT, 6-MP-MSNSN-MTX gradually releases 6-MP. In rat plasma, 6-MP-MSNSN-MTX effectively inhibits the metabolic deactivation of 6-MP and MTX. 6-MP-MSNSN-MTX could be an agent for long-acting chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23680872     DOI： 10.1039/c3nr00227f

Source DB:  PubMed          Journal:  Nanoscale        ISSN： 2040-3364            Impact factor:   7.790


  5 in total

1.  Gene-silencing effects of anti-survivin siRNA delivered by RGDV-functionalized nanodiamond carrier in the breast carcinoma cell line MCF-7.

Authors:  Yanzhao Bi; Yifan Zhang; Chunying Cui; Lulu Ren; Xueyun Jiang
Journal:  Int J Nanomedicine       Date:  2016-11-04

2.  Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo.

Authors:  Qi Sun; Xiaoli Wang; Chunying Cui; Jing Li; Yifan Wang
Journal:  Int J Nanomedicine       Date:  2018-06-27

3.  Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo.

Authors:  Xiaoli Wang; Qi Sun; Chunying Cui; Jing Li; Yifan Wang
Journal:  Drug Des Devel Ther       Date:  2018-09-07       Impact factor: 4.162

4.  Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.

Authors:  Yaru Zou; Dong Mei; Jinjie Yuan; Jiaqi Han; Jiamin Xu; Ning Sun; Huan He; Changqing Yang; Libo Zhao
Journal:  Int J Nanomedicine       Date:  2021-02-12

5.  Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis.

Authors:  Shan Li; Yuji Wang; Feng Wang; Yaonan Wang; Xiaoyi Zhang; Ming Zhao; Qiqi Feng; Jianhui Wu; Shurui Zhao; Wei Wu; Shiqi Peng
Journal:  Int J Nanomedicine       Date:  2015-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.